Table of Contents
Chapter 1. Global Central Nervous System Therapeutics Market Executive Summary
1.1 Global CNS Therapeutics Market Size & Forecast (2024-2032)
1.2 Regional Summary
1.3 Segmental Summary
1.3.1 By Disease Outlook
1.4 Key Trends
1.5 Recession Impact
1.6 Analyst Recommendations & Conclusion
Chapter 2. Global Central Nervous System Therapeutics Market Definition and Research Assumptions
2.1 Research Objective
2.2 Market Definition
2.3 Research Assumptions
2.3.1 Inclusion & Exclusion
2.3.2 Limitations
2.3.3 Supply Side Analysis
2.3.3.1 Availability
2.3.3.2 Infrastructure
2.3.3.3 Regulatory Environment
2.3.3.4 Market Competition
2.3.3.5 Economic Viability
2.3.4 Demand Side Analysis
2.3.4.1 Regulatory Frameworks
2.3.4.2 Technological Advancements
2.3.4.3 Environmental Considerations
2.3.4.4 Consumer Awareness & Acceptance
2.4 Estimation Methodology
2.5 Years Considered for the Study
2.6 Currency Conversion Rates
Chapter 3. Global Central Nervous System Therapeutics Market Dynamics
3.1 Market Drivers
3.1.1 Growing Prevalence of CNS Disorders
3.1.2 Rising Approvals of Generic Drugs
3.1.3 Technological Advancements in Drug-Delivery Systems
3.2 Market Challenges
3.2.1 Regulatory Hurdles
3.2.2 High Cost of Different Therapies
3.3 Market Opportunities
3.3.1 Expansion of Healthcare Infrastructure in Emerging Markets
3.3.2 Increasing Awareness of Mental Health
Chapter 4. Global Central Nervous System Therapeutics Market Industry Analysis
4.1 Porter's Five Forces Model
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Buyers
4.1.3 Threat of New Entrants
4.1.4 Threat of Substitutes
4.1.5 Competitive Rivalry
4.2 PESTEL Analysis
4.2.1 Political
4.2.2 Economic
4.2.3 Social
4.2.4 Technological
4.2.5 Environmental
4.2.6 Legal
4.3 Top Investment Opportunities
4.4 Top Winning Strategies
4.5 Disruptive Trends
4.6 Industry Expert Perspective
4.7 Analyst Recommendations & Conclusion
Chapter 5. Global Central Nervous System Therapeutics Market Size & Forecasts by Disease Outlook (2024-2032)
5.1 Segment Dashboard
5.2 Global CNS Therapeutics Market: Disease Outlook Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1 Neurovascular Diseases
5.2.2 CNS Trauma
5.2.3 Mental Health
5.2.4 Neurodegenerative Diseases
5.2.5 Infectious Diseases
5.2.6 CNS Cancer
5.2.7 Others
Chapter 6. Global Central Nervous System Therapeutics Market Size & Forecasts by Region (2024-2032)
6.1 North America CNS Therapeutics Market
6.1.1 U.S. CNS Therapeutics Market
6.1.1.1. Distribution Channel breakdown size & forecasts, 2024-2032
6.1.2 Canada CNS Therapeutics Market
6.2 Europe CNS Therapeutics Market
6.2.1 U.K. CNS Therapeutics Market
6.2.2 Germany CNS Therapeutics Market
6.2.3 France CNS Therapeutics Market
6.2.4 Spain CNS Therapeutics Market
6.2.5 Italy CNS Therapeutics Market
6.2.6 Rest of Europe CNS Therapeutics Market
6.3 Asia Pacific CNS Therapeutics Market
6.3.1 China CNS Therapeutics Market
6.3.2 India CNS Therapeutics Market
6.3.3 Japan CNS Therapeutics Market
6.3.4 Australia CNS Therapeutics Market
6.3.5 South Korea CNS Therapeutics Market
6.3.6 Rest of Asia Pacific CNS Therapeutics Market
6.4 Latin America CNS Therapeutics Market
6.4.1 Brazil CNS Therapeutics Market
6.4.2 Mexico CNS Therapeutics Market
6.4.3 Rest of Latin America CNS Therapeutics Market
6.5 Middle East & Africa CNS Therapeutics Market
6.5.1 Saudi Arabia CNS Therapeutics Market
6.5.2 South Africa CNS Therapeutics Market
6.5.3 Rest of Middle East & Africa CNS Therapeutics Market
Chapter 7. Competitive Intelligence
7.1 Key Company SWOT Analysis
7.2 Top Market Strategies
7.3 Company Profiles
7.3.1 Biogen
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Market Strategies
7.3.2 Otsuka Pharmaceutical Co., Ltd.
7.3.3 Eli Lilly and Company
7.3.4 Johnson & Johnson Services, Inc.
7.3.5 Pfizer, Inc.
7.3.6 Novartis International AG
7.3.7 Roche Holding AG
7.3.8 Teva Pharmaceutical Industries Ltd.
7.3.9 Merck & Co., Inc.
7.3.10 Bristol-Myers Squibb Company
7.3.11 AbbVie Inc.
7.3.12 Sanofi S.A.
7.3.13 Amgen Inc.
7.3.14 AstraZeneca PLC
7.3.15 GlaxoSmithKline plc (GSK)
Chapter 8. Research Process
8.1 Research Process
8.1.1 Data Mining
8.1.2 Analysis
8.1.3 Market Estimation
8.1.4 Validation
8.1.5 Publishing
8.2 Research Attributes